Longevity & Aging158 Alzheimer's Drugs Now in Clinical Trials as Pipeline Grows 40% Over a Decade
Researchers tracking Alzheimer's drug development report a significant expansion in clinical trials, with 158 drugs now being tested across 192 trials as of early 2026. Over the past decade, the number of trials grew by 35% and tested agents by 40%. The pipeline has shifted notably: inflammation and immune-targeting drugs rose from 6% to 20% of candidates, while amyloid-focused therapies declined from 33% to 20%. About 35% of drugs being tested are repurposed from other approved conditions. Experts highlight combination therapies as the likely future direction, given that Alzheimer's involves multiple overlapping biological processes including neuroinflammation, amyloid buildup, and tau tangles. The disease is projected to affect over 90 million Americans by 2060 across its full spectrum.
